These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25286755)

  • 21. Epidermal Growth Factor Receptor Gene Mutation Detection in Histology and Cytology Specimens of Primary Lung Adenocarcinoma: Immunohistochemistry Versus the Molecular Method.
    Abdul Hamid NS; Mat Zin AA
    Asian Pac J Cancer Prev; 2021 Jun; 22(6):1935-1942. PubMed ID: 34181354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma.
    Wen YH; Brogi E; Hasanovic A; Ladanyi M; Soslow RA; Chitale D; Shia J; Moreira AL
    Mod Pathol; 2013 Sep; 26(9):1197-203. PubMed ID: 23599147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular diagnostic algorithm for epidermal growth factor receptor mutation detection in Asian lung adenocarcinomas: comprehensive analyses of 445 Taiwanese patients with immunohistochemistry, PCR-direct sequencing and Scorpion/ARMS methods.
    Ho HL; Chang FP; Ma HH; Liao LR; Chuang YT; Chang-Chien YC; Lin KY; Chou TY
    Respirology; 2013 Nov; 18(8):1261-70. PubMed ID: 23796143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitive detection of EGFR mutations in cerebrospinal fluid from lung adenocarcinoma patients with brain metastases.
    Yang H; Cai L; Zhang Y; Tan H; Deng Q; Zhao M; Xu X
    J Mol Diagn; 2014 Sep; 16(5):558-563. PubMed ID: 24994671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer.
    Simonetti S; Molina MA; Queralt C; de Aguirre I; Mayo C; Bertran-Alamillo J; Sanchez JJ; Gonzalez-Larriba JL; Jimenez U; Isla D; Moran T; Viteri S; Camps C; Garcia-Campelo R; Massuti B; Benlloch S; Ramon y Cajal S; Taron M; Rosell R
    J Transl Med; 2010 Dec; 8():135. PubMed ID: 21167064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer.
    Jiang G; Fan C; Zhang X; Dong Q; Wang L; Liu Y; Dai S; Yang L; Zhang Y; Yu J; Wang E
    PLoS One; 2013; 8(3):e59183. PubMed ID: 23536868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Raman spectroscopy for diagnosing EGFR mutation status in lung adenocarcinoma.
    Wang L; Zhang Z; Huang L; Li W; Lu Q; Wen M; Guo T; Fan J; Wang X; Zhang X; Fang J; Yan X; Ni Y; Li X
    Analyst; 2014 Jan; 139(2):455-63. PubMed ID: 24303521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.
    Wang J; Cai Y; Dong Y; Nong J; Zhou L; Liu G; Su D; Li X; Wu S; Chen X; Qin N; Zeng X; Zhang H; Zhang Z; Zhang S
    PLoS One; 2014; 9(7):e101551. PubMed ID: 24992725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of epidermal growth factor receptor mutations in lung adenocarcinoma cytological specimens by immunocytochemistry.
    Yoshida M; Nagatomo T; Ohnishi T; Kawashima M; Naitoh A; Morii E
    Mol Clin Oncol; 2017 Dec; 7(6):981-987. PubMed ID: 29285360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma.
    Allo G; Bandarchi B; Yanagawa N; Wang A; Shih W; Xu J; Dalby M; Nitta H; To C; Liu N; Sykes J; Tsao MS
    Histopathology; 2014 May; 64(6):826-39. PubMed ID: 24251405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A simple and sensitive method for detecting major mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene in non-small-cell lung carcinoma.
    Ohnishi H; Ohtsuka K; Ooide A; Matsushima S; Goya T; Watanabe T
    Diagn Mol Pathol; 2006 Jun; 15(2):101-8. PubMed ID: 16778591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas.
    Wu Z; Bai F; Fan L; Pang W; Han R; Wang J; Liu Y; Yan X; Duan H; Xing L
    Hum Pathol; 2015 Dec; 46(12):1935-44. PubMed ID: 26475093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?
    Zhang Y; Ma Y; Li Y; Shen X; Yu Y; Pan Y; Zhang Y; Yu S; Zheng D; Zhao Y; Hu H; Sun Y; Zhang Y; Xiang J; Chen H
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):165-171. PubMed ID: 29026990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidermal Growth Factor Receptor Gene Mutation in Pleural Lavage Cytology Findings of Primary Lung Adenocarcinoma Cases.
    Inoue T; Matsumura Y; Araki O; Karube Y; Maeda S; Kobayashi S; Chida M
    Ann Thorac Cardiovasc Surg; 2018 Feb; 24(1):1-5. PubMed ID: 29093430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer.
    Houang M; Sioson L; Clarkson A; Watson N; Farzin M; Toon CW; Raut A; O'Toole SA; Cooper WA; Pavlakis N; Mead S; Chou A; Gill AJ
    Pathology; 2014 Oct; 46(6):501-8. PubMed ID: 25158821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation.
    Ono A; Kenmotsu H; Watanabe M; Serizawa M; Mori K; Imai H; Taira T; Naito T; Murakami H; Nakajima T; Ohde Y; Endo M; Yamamoto N; Koh Y; Takahashi T
    Ann Oncol; 2014 Oct; 25(10):1948-1953. PubMed ID: 25009007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.